Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 20, 2023 06:55 ET | Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 07, 2023 06:57 ET | Synlogic, Inc.
– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE...
Stacked logo.png
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
December 15, 2022 19:01 ET | Sosei Group Corporation
New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible...
Human Microbiome Market is expected to foster up to a landmark of USD 1318.72 Million by 2030 with a CAGR value of around 31.08%.
New York, United States, May 24, 2022 (GLOBE NEWSWIRE) -- A Human Microbiome comprises archaea, viruses, bacteria, & eukaryotes which reside within & outside our body system. These organisms...
 Inventiva announces
 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
March 08, 2022 02:00 ET | INVENTIVA
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ...
Inventiva annonce qu
Inventiva annonce que la FDA accepte sa demande d’« Investigational New Drug » pour l’essai clinique de Phase II combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de diabète de type 2
March 08, 2022 02:00 ET | INVENTIVA
L’évaluation de la Food and Drug Administration (FDA) est favorable à la poursuite de l’essai clinique combiné LEGEND Le lancement de l’étude est prévu pour S1 2022 et la publication des premiers...
Vantage Market Research.png
Global Artificial Intelligence (AI) in Drug Discovery Market ($4197.5 Mn by 2028) Growth Forecast at 41.5% CAGR During 2022 to 2028 COVID Impact and Global Analysis by Vantage Market Research
March 03, 2022 04:49 ET | Vantage Market Research
WASHINGTON, March 03, 2022 (GLOBE NEWSWIRE) -- The Global Artificial Intelligence in Drug Discovery Market size is expected to reach USD 4,197.5 Million by 2028, exhibiting a Compound Annual Growth...
BioRestorative Therapies Announces Closing of $23 Million Public Offering
November 09, 2021 14:20 ET | BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
Wereldhave commits to setting Science-Based Targets
March 13, 2020 03:29 ET | Wereldhave N.V.
Press release | Wereldhave commits to setting Science-Based TargetsWereldhave is pleased to announce it has committed itself to reduce carbon emissions to a level in line with what climate science...
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
January 21, 2020 09:15 ET | Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...